New Immune-Calming vaccine shows promise for progressive MS
NCT ID NCT07020715
First seen Jan 11, 2026 · Last updated Apr 30, 2026 · Updated 15 times
Summary
This early-phase trial tests a personalized cell therapy for people with progressive multiple sclerosis (MS). The treatment uses the patient's own immune cells, trained with vitamin D3 and myelin proteins, to calm the immune system and slow disability. The study will enroll 14 adults aged 18–65 with progressive MS and no recent relapses, monitoring safety and disability progression over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Germans Trias i Pujol Hospital (HUGTiP)
Badalona, 08916, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
Universitair Ziekenhuis Antwerpen (UZA)
Edegem, 2650, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.